Lipo-PM Is a night-time weight loss formula by Applied Nutraceuticals containing just four ingredients. Unlike most night-time weight loss supplements, Lipo-PM targets blood glucose, something that can actually be managed during sleep. This is different from most night-time fat-burners which contain ingredients that require exercise…[Skip to the Bottom Line]
GREEN TEA EXTRACT:
The primary compound present in Green Tea Extract, responsible for the weight-loss benefits, is Epigallocatechin gallate (EGCG).
A 2009 study, published in “The Journal of Nutrition”, found that subjects consuming 625mg Green Tea Catechins (EGCG) alongside 40mg Caffeine paired with exercise lost an average of 2.2kg (4.8lbs) compared to the subjects in the control group (consuming just Caffeine), who lost an average of 1kg (2.2lbs). These findings were corroborated by a 2009 meta-analysis, published in the “International Journal of Obesity”, which concluded that Green Tea extract tended to cause about 1.2kg (2.6lbs) reduction in bodyweight, and that effects could be amplified with Caffeine in non-caffeine tolerant individuals.
Further research has revealed that EGCG can effectively block Catechol-o-Methyl Transferase (COMT), the enzyme responsible for the degradation of Catcholamines such as Noradrenaline. The result is an indirect increase in Noradrenaline which induces lipolysis. So, while EGCG is not likely to induce noticeable weight-loss alone, when combined with Caffeine or other Noradrenaline-releasing stimulants, it can be quite synergistic. Most of the efficacy has been demonstrated using doses of 400-500mg EGCG daily, and the less caffeine-tolerant the individual, the better.
While EGCG does possess some weight-loss benefit, it must be combined with other stimulants or, at the very least, with exercise, to truly be effective. Given that Lipo PM is a night-time formula, it is not likely that the EGCG will be facilitating much fat-loss from exercise, but may extend the Dopamine-rise from Mucuna Pruriens.
Mucuna Pruriens contains L-Dopa, a direct precursor to Dopamine which may favorably influence quality of sleep. However, in the context of Lipo PM, Applied Nutraceuticals is primarily concerned with preliminary research that indicates Mucuna Pruriens can regulate blood glucose as well.
A 2002 study from “Phytotherapy Research” found a notable blood-glucose lowering effect at a dose of 200mg/kg over a 15 day period in diabetic mice.
These results were replicated in a 2011 study, published in the “Asian Pacific Journal of Tropical Medicine”, in which Mucuna Pruriens was able to reduce blood glucose spikes following meals at doses ranging from 5 to 100mg/kg (dose dependent), also in Diabetic rats.
While most of the research regarding the blood glucose lowering effects of Mucuna Pruriens has been conducted in Diabetic mice, a 2008 study from “Fitoterapia” concluded that these effects were apparent in non-diebetic mice, although perhaps to a milder degree.
While the mechanisms by which Mucuna Pruriens works is not 100% understood, the majority of the research indicates that it can increase the activity of several liver enzymes involved in carbohydrate (sugar) metabolism. Lipo PM, contains an undisclosed amount of Mucuna Pruriens, but given its position in the 600mg proprietary blend, there is certainly room for an effective dose.
Bacopa Monnieri is an herb which has traditionally been used as a nootropic and anxiolytic. However, in the context of Lipo PM, Applied Nutraceuticals claims that Bacopa Monnieri is able to influence Thyroid Hormones, thus positively impacting body weight. A 2002 study from “Ethnopharmacology” found that 200mg/kg daily of Bacopa Extract was able to raise T4 (a Thryoid Hormone) by about 42% in male mice. Currently, the effects of Bacopa on Thyroid hormones have not been studied in human subjects, and it is unknown how beneficial it can be for weight loss. Logically, the most likely individuals to benefit from Bacopa supplementation would be those with Thyroid issues and abnormally low levels of T4.
Given that Lipo PM cannot possibly contain the same relative dose (200mg/kg) of Bacopa used in the above mentioned study, it is unlike that any comparable effects would occur. Still, it’s possible that there is some benefit to be obtained here.
Banaba is generally standardized for the active component, Corosolic Acid, which is alleged to have blood glucose lowering capabilities. A 2006 study, published in “Diabetes Research and Clinical Practice”, found that 10mg Corosolic Acid prior to a Glucose Tolerance Test (75g Glucose) caused significant reductions in blood Glucose levels which were still present at the 90 minute mark. Several other studies, both animal and human, have confirmed similar effects, although some studies are confounded with the use of other substances.
Unfortunately, Applied Nutraceuticals does not disclose the Corosolic Acid content of this particular type of Banaba, so it’s difficult to draw any solid conclusions here.
THE BOTTOM LINE:
Lipo PM is actually one of the more potentially effective night-time weight-loss formulas we’ve come across, mostly due to the approach that Applied Nutraceuticals has taken with the product. Most night-time fat-burners try to include non-stimulant ingredients that allegedly support fat-burning from exercise. The obvious flaw with this approach is that you’re not exercising when your asleep, so there is no fat-burning going on to support. Lipo PM, on the other hand, is primarily designed to keep glucose levels in check, a function which still has value at night (especially if you eat shortly before bed). The results are not going to be drastic, and in some cases may not even be all that noticeable, but over-time Lipo-PM may provide some modest benefit. At about 15 cents per serving, Lipo PM is not insanely over-priced, as are some other products that make similar claims, and may be worth a shot for those with less than optimal insulin sensitivity.
[expand title=”REFERENCES” tag=”h5″]
- Keränen, Tapani, et al. “Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.” European journal of clinical pharmacology 46.2 (1994): 151-157.
- Brown, A. L., et al. “Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial.” British Journal of Nutrition106.12 (2011): 1880-1889.
- Maki, Kevin C., et al. “Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults.” The Journal of nutrition 139.2 (2009): 264-270.
- Thielecke, Frank, et al. “Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study.” European journal of clinical nutrition 64.7 (2010): 704-713.
- Hursel, R., W. Viechtbauer, and M. S. Westerterp-Plantenga. “The effects of green tea on weight loss and weight maintenance: a meta-analysis.”International journal of obesity 33.9 (2009): 956-961.
- Lu, Hong, Xiaofeng Meng, and Chung S. Yang. “Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (−)-epigallocatechin gallate.” Drug metabolism and disposition 31.5 (2003): 572-579.
- Majekodunmi, Stephen O., et al. “Evaluation of the anti–diabetic properties of< i> Mucuna pruriens seed extract.” Asian Pacific journal of tropical medicine4.8 (2011): 632-636.
- Rathi, S. S., J. K. Grover, and V. Vats. “The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism.” Phytotherapy Research 16.3 (2002): 236-243.
- Bhaskar, Anusha, V. G. Vidhya, and M. Ramya. “Hypoglycemic effect of< i> Mucuna pruriens seed extract on normal and streptozotocin-diabetic rats.”Fitoterapia 79.7 (2008): 539-543.
- Kar, A., S. Panda, and S. Bharti. “Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice.”Journal of ethnopharmacology 81.2 (2002): 281-285.
- Fukushima, M., et al. “Effect of corosolic acid on postchallenge plasma glucose levels.” Diabetes research and clinical practice 73.2 (2006): 174-177.